Spinraza (Nusinersen) Access Update: What Patients Need to Know in 2026

The Spinraza (nusinersen) treatment landscape has changed meaningfully in 2026. On March 30, 2026, the FDA approved a new High Dose Regimen of Spinraza, expanding treatment options for patients with spinal muscular atrophy. Meanwhile, the broader SMA treatment landscape is more competitive than ever, with new gene therapy options and evolving insurer coverage policies affecting how patients access all SMA therapies.

Here is a comprehensive update on what patients need to know about Spinraza access in 2026.

Major Update: FDA Approves High-Dose Spinraza Regimen in March 2026

On March 30, 2026, Biogen announced FDA approval of the High Dose Regimen of Spinraza. This new regimen consists of two 50 mg loading doses administered 14 days apart, followed by 28 mg maintenance dose injections every four months. This is distinct from the existing Low Dose Regimen (four 12 mg loading doses, then 12 mg every four months) that has been available since 2016.

The high-dose regimen was developed based on data from the DEVOTE trial — a Phase 2/3 study that enrolled 145 participants across a range of ages and SMA types. In the pivotal Part B cohort, treatment-naive infants with infantile-onset SMA receiving the high-dose regimen showed statistically significant motor function improvement compared to a matched sham control group from the ENDEAR study, with a mean difference of 26.19 points on the CHOP-INTEND scale.

The high-dose regimen was already approved in the European Union, Switzerland, and Japan before receiving U.S. approval. It will be available in the U.S. in the coming weeks, according to Biogen.

What Does the High-Dose Approval Mean for Current Patients?

For patients already on the low-dose Spinraza regimen, the high-dose approval does not automatically change your treatment. However, it opens a new conversation with your SMA specialist about whether switching to the higher dose might offer additional benefits — particularly for patients who have experienced a plateau in motor function improvement on the 12 mg regimen.

For treatment-naive patients starting Spinraza for the first time, your neurologist can now choose between the two regimens based on your individual clinical situation. The accelerated loading phase of the high-dose regimen (just two loading doses over 14 days vs. four over approximately two months for low-dose) may be advantageous for some newly diagnosed patients.

Is Spinraza in Shortage in 2026?

As of 2026, Spinraza is not on the FDA's drug shortage list. The drug is supplied through a specialty distribution network directly to treatment centers, and Biogen has not reported any supply disruptions. However, access challenges persist for many patients — primarily due to insurance prior authorization requirements, out-of-pocket costs, and the limited number of certified SMA treatment centers in some regions.

Unlike many drugs where access is limited by physical supply, Spinraza's access challenges are predominantly administrative and financial. This means that with the right support (see below), most patients can navigate these barriers successfully.

How the New SMA Treatment Landscape Affects Spinraza Access

With the November 2025 FDA approval of Itvisma (intrathecal onasemnogene abeparvovec), patients 2 years and older now have a one-time gene therapy option. This approval — combined with the expanding use of risdiplam (Evrysdi) — means insurers are now managing more complex coverage decisions across three therapy categories: ongoing SMN2-modifying agents (Spinraza, Evrysdi), and one-time gene therapies (Zolgensma, Itvisma).

For some insurers, this competitive landscape may lead to step therapy requirements — meaning you may be required to try one therapy before gaining coverage for another. Be prepared for this possibility when working with your insurer.

Insurance Coverage for Spinraza in 2026

Spinraza remains covered by Medicare Part B (billed under HCPCS code J2326) and by most commercial insurance plans, but prior authorization is universally required. Key insurance considerations in 2026:

Commercial insurance: Requires prior authorization. Cigna's most recent policy (effective August 2025) requires confirmed SMA genetic diagnosis, documented SMN2 copy number, and documented clinical benefit at each renewal.

Medicare: Covered under Part B with a 20% coinsurance after deductible. Medicare Part D has a $2,100 out-of-pocket cap in 2026.

Medicaid: Coverage varies by state. Many state Medicaid programs cover Spinraza but may have additional criteria or quantity limits.

Financial Assistance Options Available in 2026

The extreme cost of Spinraza has driven the development of several financial support mechanisms:

Biogen SMA360°: Co-pay assistance for commercially insured patients; patient assistance program for uninsured/underinsured. Call 844-477-4672.

Cure SMA financial assistance: Cure SMA (curesma.org) offers advocacy and financial resources for SMA patients.

HealthWell Foundation: Offers premium assistance and co-pay support for qualifying SMA patients.

How medfinder Helps Patients Access Spinraza

Navigating the complexities of Spinraza access — from insurance authorization to finding the right treatment center — is exactly what medfinder is designed to help with. As a paid service, medfinder calls on your behalf to identify the right resources and pharmacies that can support your access journey.

Also see: Alternatives to Spinraza If You Can't Fill Your Prescription for information on risdiplam, Zolgensma, and Itvisma.